louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05053243: Clinical Validation of the AliveCor Kardia 12L and 6L Devices
Official title: Clinical Validation of the AliveCor Kardia 12L and 6L Devices
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arrhythmia
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
First posted: 2021-09-22
Enrollment: 221
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: AliveCor (www.alivecor.com) has developed an ECG device (KardiaMobile) that interfaces with iOS and Android smartphones and tablets. This ECG consists of a lightweight hardware case with two metal electrodes that can snap onto the back of the phone and a software application. By holding the right finger(s) on the right electrode and the left finger(s) on the left electrode, an electrical circuit is completed and a lead-I, 30 second rhythm strip is created. KardiaMobile and a newer device, KardiaMobile 6L, were approved by FDA for ECG rhythm recording. Recently, AliveCor developed two new devices: Kardia 12L and Kardia 6L to record 12- lead and 6-lead ECGs, respectively. However, the data generated from the two new devices have not yet been validated for accuracy. The purpose of this study is to evaluate the accuracy of the ECGs recorded by AliveCor Kardia 12L and 6L devices. This will be compared to simultaneous standard of-care 12-lead ECG recordings. The ECGs will be analyzed for accuracy and statistical difference using root-mean-square error and cross correlation between the median beats.


Eligibility criteria: Inclusion Criteria:

1. Male and female patients 18 years old or older
2. Ability to sit for an ECG and AliveCor Kardia 12L and Kardia 6L recordings for 20 minutes

Exclusion Criteria:

1. Any internal stimulator that would generate electrical interference with the recording system of the AliveCor Kardia 12L or Kardia 6L.
2. Open chest wounds or recent (\<30 days) surgery to the chest or abdomen.
3. Absence of any limb that would require modification of the lead set-up

Primary outcomes:
measure: Agreement on QRS width between Kardia 12L and ECG
timeFrame: 30 seconds
measure: Agreement on PR interval between Kardia 12L and ECG
timeFrame: 30 seconds
measure: Agreement on QT interval between Kardia 12L and ECG
timeFrame: 30 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: University of Oklahoma
name: Stavros Stavrakis, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02286843: Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Official title: Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer Metastases
HER2 Positive Breast
Keywords: 89Zr-trastuzumab
PET/CT
14-156
89Zr-pertuzumab
HER2-targeted
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
name: Genentech, Inc.
First posted: 2014-11-10
Enrollment: 49
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.


Eligibility criteria: Inclusion Criteria:

* Women age \> 18
* Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic disease.
* 5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)
* ECOG performance score of 0-2

Exclusion Criteria:

* Life expectancy \< 3months
* Pregnancy or lactation
* Patients who cannot undergo PET/CT scanning because of weight limits
* CNS only disease on recent imaging

Primary outcomes:
measure: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Gary Ulaner, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology. 2020 Aug;296(2):370-378. doi: 10.1148/radiol.2020192828. Epub 2020 Jun 9.
citation: Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.
Clinical trial NCT05418543: CH-EUS in Diagnosis of Inoperable Bile Duct Tumors
Official title: Contrast-enhanced Endoscopic Ultrasound in Diagnosis of Inoperable Bile Duct Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Inoperable Disease
Bile Duct Cancer
Lead sponsor: Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Sponsor class: OTHER
First posted: 2022-06-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: VALIDATION OF THE SUPERIORITY OF CONTRAST ENHANCED ENDOSCOPY TO STANDARD ENDOSCOPY IN THE DIAGNOSIS OF BILE DUCT TUMORS


Eligibility criteria: Inclusion Criteria:

* Bile duct tumor diagnosed at endoscopic US, CT scan or MRI
* INR\<1.5; platelets \> 50.000
* written consent form

Exclusion Criteria:

* INR\>1.5; platelets \< 50.000
* duodenal invasion or stenosis
* patients denial
* previous treatment for hepato-biliary tumors

Primary outcomes:
measure: CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors
timeFrame: one week
Secondary outcomes:
Other outcomes:
Locations:
city: Cluj-Napoca
country: Romania
facility: IRGH "O. Fodor"
state: Cluj
Study officials:
affiliation: andradaseicean@gmail.com
name: Andrada Seicean, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03200743: Catestatin and Hypertension in Pregnancy
Official title: Relationship Between Catestatin and Pregnant Hypertensive Disorders
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pre-Eclampsia
Eclampsia
Hypertension, Pregnancy-Induced
Hypertension in Pregnancy
Keywords: Hypertension
Pregnancy
Catestatin
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2017-06-27
Enrollment: 400
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients hospitalized in Peking University Third Hospital maternity ward after May, 2017

Brief summary: Catestatin is a kind of protein involved with cardiovascular disease. Accumulated evidence shows that Catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders needs to be determined. By measuring the plasma level of Catestatin, main biochemical marks and UCG in healthy pregnancy and pregnancy with hypertension, the research may contribute to this problem.


Eligibility criteria: Inclusion Criteria:

* Healthy pregnancy women
* Pregnancy women with hypertension

  1. Despite the pregnant gestational age , systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured three times more than 24 hours apart
  2. Pregnant gestational age \> 20 weeks, systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured twice more than 4 hours apart

Exclusion Criteria:

* Lack of blood sample at the specified enrollment period
* Women who refuse the study
* Other illness which needs medications interfering with blood pressure (eg: Asthma requiring systemic steroids)
* Known coronary artery disease or heart failure
* Serious medical illness (eg: renal insufficiency, congestive heart disease, chronic respiratory insufficiency, uncontrolled infection).
* multiple endocrine neoplasia or Cushing's syndrome or mixed tumours or pheochromocytoma or medullary thyroid carcinoma.
* previous history of malignant tumour, with the exception of carcinoma in situ of the uterine cervix or non-melanoma skin cancer
* renal insufficiency

Primary outcomes:
measure: plasma level of Catestatin
timeFrame: once at the specified enrollment period
Secondary outcomes:
measure: blood pressure
timeFrame: the specified enrollment period,42 days and 2 months after the pregnancy
Other outcomes:
Locations:
city: Beijin
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT02776943: UCMSC Transplantation in the Treatment of Cartilage Damage
Official title: Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Implantation in the Treatment of Articular Cartilage Defect of Knee and Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Cartilage Damage
Degenerative Osteoarthritis
Lead sponsor: South China Research Center for Stem Cell and Regenerative Medicine
Sponsor class: OTHER
First posted: 2016-05-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy and safety of transplantation of umbilical cord mesenchymal stem cells（UCMSCs） in patient with Knee cartilage damage.

Detailed description: Human cartilage only has limited regenerative potential. Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) is a promising strategy given the high proliferative capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. The acquisition of ucMSCs does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. The investigators inject allogeneic human mesenchymal stem cells to the cartilage lesions in patients via intra-articular injection method, and to investigate the efficacy and safety。

Eligibility criteria: Inclusion Criteria:

* Patients whose lesion (single joint) should be in the range of 2 cm\^2-8 cm\^2.
* Patients with pain in affected joint of 60 mm- 100 mm VAS (visual analogue scale)
* Patients with articular swelling, tenderness and active range of motion of Grade 2 or below
* Patients with knee joint cartilage defect or injury of ICRS (International Cartilage Repair Society) Grade 4 confirmed by arthroscopy (At screening, patients diagnosed as such with an MRI may be included)
* Patients who needs invasive interventions of arthroplasty due to no response from existing pain medication
* Patients voluntarily agreed to participate in the study and signed informed consent

Exclusion Criteria:

* Patients with autoimmune diseases or medical history
* Patients with infections requiring injection of antibiotics
* Patients with severe internal diseases
* Patients who are currently pregnant or lactation
* Patients who had participated in any other clinical trials within the past four weeks
* Patients who had been administered with immunosuppressants within the past four weeks
* Patients whom the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above

Primary outcomes:
measure: Knee Function Change and Improvement
timeFrame: 12 months after treatment
measure: Knee Function Change and Improvement
timeFrame: 12 months after treatment
Secondary outcomes:
measure: Severity of adverse events
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02438943: An Intervention to Improve Management of Dyslipidemia in Primary Care
Official title: A Cluster Randomized Controlled Trial of an Intervention to Improve the Management of Dyslipidemia in Primary Care
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiovascular Disease
Dyslipidemia
Diabetes Melletus
Obesity
Lead sponsor: The University of The West Indies
Sponsor class: OTHER
First posted: 2015-05-08
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To assess the effectiveness of a clinical audit and physician based intervention in improving the management of dyslipidemia at Health centres in the Southeast Health Region of Jamaica


Eligibility criteria: Inclusion Criteria:

* Attended the clinic for at least 18 months
* Is diagnosed with any of hypertension, diabetes, dyslipidemia, stroke, coronary heart disease (including angina, myocardial infarction), congestive cardiac failure or peripheral arterial disease, were eligible to be included in the audit

Exclusion Criteria:

* acutely ill or was diagnosed with established kidney disease

Primary outcomes:
measure: Proportion of persons attending health centers in the Southeast Health region with normal lipid values
timeFrame: 1 year
Secondary outcomes:
measure: Proportion of persons attending health centers in the Southeast Health region with normal glucose values
timeFrame: 1 year
measure: Proportion of persons attending health centers in the Southeast Health region with normal blood pressure values
timeFrame: 1 year
Other outcomes:
Locations:
city: Kingston
country: Jamaica
facility: University of the West Indies, mona
Study officials:
References:
Clinical trial NCT04331743: A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
Official title: A Single-arm, Open-label, Single-center Phase Ib Study to Evaluate the Safety and Efficacy of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Advanced Hepatocellular Carcinoma (HCC)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Hepatocellular Carcinoma
Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-04-02
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide RP2D. PLM60 is to administered by multi-cycle intravenous infusion.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent from the patient；
* ECOG performance status of 0 or 1;
* Histologically/cytologically confirmed diagnosis of advanced HCC;
* Adequate washout period for previous anti-tumor therapy;
* Measurable disease according to RECIST v1.1;
* Life expectancy ≥ 12 weeks;
* Adequate organ function;
* Child-Pugh grade A or partial grade B; BCLC stage B or C;V

Exclusion Criteria:

* Prior treatment with Mitoxantrone or Liposome-entrapped Mitoxantrone, or other anthracyclines, with the total cumulative dose of \> 360 mg/m2 ;
* Any drug-related adverse event derived from any previous anti-tumor treatment, excluding alopecia, Pigmentation, or other toxicity with little safety risk for subjects, that has not recovered to grade1 or less;
* Active central nervous system (CNS) metastases (brain or leptomeningeal metastases, etc.);
* Any history of other malignancy within 5 years;
* Untreated hepatitis infection;
* HIV positive;
* History of liver transplantation, severe cirrhosis, hepatic encephalopathy;
* Inadequate cardiac function;
* Pregnant or lactating women.

Primary outcomes:
measure: Dose-limited toxicity (DLT)
timeFrame: 1year
measure: Maximum tolerated dose (MTD)
timeFrame: 1 year
measure: Recommended Phase II Dose (RP2D)
timeFrame: 1 year
Secondary outcomes:
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 2 years
measure: Peak Plasma Concentration (Cmax)
timeFrame: 2 years
measure: Time of peak plasma concentration (Tmax)
timeFrame: 2 years
measure: Median overall survival (OS)
timeFrame: 2 years
measure: Median progression free survival (PFS)
timeFrame: 2 years
measure: Overall response rate (ORR)
timeFrame: 2 years
measure: Duration of Response (DoR)
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01773343: Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals
Official title: Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals. A Randomized Controlled Trial With Blinded Response Evaluations
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atrophic Acne Scars
Keywords: skin texture, efficacy, adverse effects
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2013-01-23
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare efficacy and adverse effects of fractional CO2 laser of acne scars treatment with 1 versus 3 months intervals

Detailed description: Change in scar texture evaluated by blinded evalutaions. Appearance of erythema, oedema, pigmentation, infection after treatment

Eligibility criteria: Inclusion Criteria:

* Have Fitzpatrick skin type I-III. (•Are male or female.
* Are between 18 and 60 years of age.
* Mild to severe acne scarring.
* Are able to read, understand, and sign the Informed Consent.
* Are willing and able to comply with all follow-up requirements -

Exclusion Criteria:

* Have had active localized or systemic infections within 6 months of enrollment
* Have compromised ability for wound healing, such as: malnutrition, oral steroid use, history of collagen vascular disease (e.g. lupus, scleroderma, history of keloid formation (raised and thickened scars), atrophic dermatitis (extreme skin irritation or itchiness) or immunologic abnormalities such as vitiligo (white patches of skin due to loss of pigment)
* Have been treated with lasers, chemical procedures, or other cosmetic procedures on the area to be treated within 6 months of enrollment
* Pregnancy

Primary outcomes:
measure: Change in scar texture
timeFrame: 24 weeks
Secondary outcomes:
measure: Appearance of erythema, oedema, pigmentation, infection
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
state: Aarhus C
Study officials:
affiliation: Aarhus University Hospital
name: Lene Hedelund, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01491243: N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy
Official title: Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Coronary Artery Disease
Keywords: contrast-induced nephropathy
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2011-12-13
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Patients who undergo urgent/emergency coronary angiography can not receive any preventive treatment of contrast induced nephropathy. We tested the hypothesis that Neutrophil gelatinase-associated lipocalin (NGAL), a new biomarker predictive for AKI, allows early and effective treatment of contrast induced nephropathy in patients with urgent/emergency coronary angiography

Detailed description: Background Patients who undergo urgent/emergency coronary angiography can not receive any preventive treatment of contrast induced nephropathy.

An acute kidney injury is generally detected too late to allow effective intervention in patients who undergo urgent/emergency coronary angiography.

Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI already shown to be useful for earlier diagnosis of contrast induced nephropathy.

Purpose The primary objective of this study is to to test the hypothesis that a NGAL-driven early intensive strategy can reduce the occurrence of contrast induced nephropathy in patients with urgent/emergency coronary angiography

Eligibility criteria: Inclusion Criteria:

* Indication to urgent/emergency coronary angiography
* Normal renal function (eGFR\> 60 ml/min/1.73 m2)
* Moderate or high Mehran's risk score for CIN (\>11).
* Able to understand and willing to sign the informed consent form

Exclusion Criteria:

• Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before

Primary outcomes:
measure: Incidence of contrast induced nephropathy
timeFrame: Baseline and 48 hours after angiography
Secondary outcomes:
measure: Post-angiographic changes in renal function parameters
timeFrame: Baseline and 48 hours after angiography
Other outcomes:
Locations:
city: Rome
country: Italy
facility: University La Sapienza
Study officials:
References:
Clinical trial NCT04963543: Evaluation of Comfort in Symptomatic Contact Lens Wearers
Official title: Evaluation of Comfort in Symptomatic Contact Lens Wearers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ocular Comfort
Keywords: Contact Lenses
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2021-07-15
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate the comfort of an ocular lubricant in symptomatic contact lens wearers. This study will be conducted in Canada.

Detailed description: The duration of individual participation is six days.

Eligibility criteria: Key Inclusion Criteria:

* Is able to understand and sign an approved information consent letter;
* Habitually wears daily disposable soft contact lenses in both eyes;
* Is able to achieve 20/40 or better monocular VA with habitual contact lenses;
* Has a pair of spectacles for vision correction.
* Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

* Routinely sleeps in habitual contact lenses;
* Has any known active ocular disease and/or infection;
* Is pregnant or lactating;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Comfort, collected for each eye
timeFrame: Up to Day 6
Secondary outcomes:
Other outcomes:
Locations:
city: Waterloo
country: Canada
facility: Alcon Investigative Site 6189
state: Ontario
Study officials:
affiliation: Alcon Research, LLC
name: Clinical Trial Lead, Dry Eye
role: STUDY_DIRECTOR
References: